The role of the ubiquitin/proteasome system in cellular responses to radiation
- 28 August 2003
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 22 (37) , 5755-5773
- https://doi.org/10.1038/sj.onc.1206676
Abstract
In the last few years, the ubiquitin(Ub)/proteasome system has become increasingly recognized as a controller of numerous physiological processes, including signal transduction, DNA repair, chromosome maintenance, transcriptional activation, cell cycle progression, cell survival, and certain immune cell functions. This is in addition to its more established roles in the removal of misfolded, damaged, and effete proteins. This review examines the role of the Ub/proteasome system in processes underlying the classical effects of irradiation on cells, such as radiation-induced gene expression, DNA repair and chromosome instability, oxidative damage, cell cycle arrest, and cell death. Furthermore, recent evidence suggests that the proteasome is a redox-sensitive target for ionizing radiation and other oxidative stress signals. In other words, the Ub/proteasome system may not simply be a passive player in radiation-induced responses, but may modulate them. The extent of the modulation will be influenced by the functional and structural diversity that is expressed by the system. Cell types vary in the Ub/proteasome structures they possess and the level at which they function, and this changes as they go from the normal to the cancerous condition. Cancer-related functional changes within the Ub/proteasome system may therefore present unique targets for cancer therapy, especially when targeting agents are used in combination with radio- or chemotherapy. The peptide boronic acid compound PS-341, which was designed to inhibit proteasome chymotryptic activity, is in clinical trials for the treatment of solid and hematogenous tumors. It has shown some efficacy on its own and in combination with chemotherapy. Preclinical studies have shown that PS-341 will also potentiate the cytotoxic effects of radiation therapy. In addition, other drugs in common clinical use have been shown to affect proteasome function, and their activities may be valuably reconsidered from this perspective.Keywords
This publication has 255 references indexed in Scilit:
- RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMONature, 2002
- A cryptic protease couples deubiquitination and degradation by the proteasomeNature, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- NF-κB at the crossroads of life and deathNature Immunology, 2002
- Defining the molecular basis of Arf and Hdm2 interactionsJournal of Molecular Biology, 2001
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999
- Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53The EMBO Journal, 1999
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- The yeast DNA repair gene RAD6 encodes a ubiquitin-conjugating enzymeNature, 1987